Rapid Generic Erosion of Branded Agents, Including Market-Leading Viagra, Will Cause Sales of Erectile Dysfunction Drugs to Remain Flat Over the Next Decade
Posted on: Monday, 19 January 2009, 07:00 CST
However, Increases in the Drug Treated Population Will Temper Losses Incurred by Leading Agents, According to a New Report from Decision Resources
The new Pharmacor report entitled Erectile Dysfunction finds that while therapeutic substitution of less-expensive, generic sildenafil for branded phosphodiesterase type 5 (PDE5) inhibitors will contribute to a significant loss of sales for Eli Lilly's Cialis and Bayer Healthcare/Schering-Plough/GlaxoSmithKline's Levitra, the availability of generic PDE5 inhibitors will encourage more patients to seek treatment for erectile dysfunction, driving increases in the diagnosed and drug-treated populations through 2017 in
According to the report, opportunity remains for emerging agents that can treat patients who do not respond to treatment with available PDE5 inhibitors or for whom these agents are contraindicated. However, several second-generation PDE5 inhibitors that are forecast to launch over the next decade are not expected to generate sufficient interest among prescribing physicians to notably offset declines anticipated in the erectile dysfunction market. Reimbursement hurdles will also constrain the market as third-party payers in
"Across the major markets under study, first-line therapies for erectile dysfunction are largely regarded as lifestyle therapies and, as such, do not qualify for reimbursement under national healthcare systems," said
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
- Soccer United Marketing and PepsiCo Renew Multi-Year Partnership
- Via TechXperts, United Marketing Group Delivers Another Market-Driven Solution For Small Businesses and Consumers
- Improved Perioperative Blood Pressure Control Associated With Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients
- Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
- This Databook Is A Detailed Information Resource Covering Current And Forecast Contact Centre Market Data
- Heritage and Granules Enter Into Strategic Alliance for the Development, Supply and Marketing of Generic Products for the U.S. Market
- Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF-Alpha Inhibitors to $1.3 Billion in the Market to Treat Crohn's Disease
- FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
- Verizon and DIRECTV to Offer Competitive Service Bundle to Beat Cable 'Triple Play' in Multidwelling-Unit Market
 |
 |
User Comments (0)
RSS Feeds